TEL AVIV, July 19 (Reuters) – Teva Pharmaceutical Industries
Ltd said on Tuesday it successfully priced a debt
offering for $15 billion worth of senior notes to help fund its
acquisition of Allergan…

The post Teva Pharm prices $15 bln in notes to fund Allergan generics deal appeared first on NASDAQ.